ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2008 Chicago Multidisciplinary Symposium in Thoracic Oncology

Click here to go to the previous page

General Session V: Challenges in New Drug Development - Imaging and Biomarkers

Track : General Session

Program Code: 080

Date: Thursday, November 13, 2008

Time: 2:15 PM to 3:45 PM EST

Duration: 2390 Minutes

Location: Grand Ballroom 1/II

SPEAKER(S):

Click the plus sign to see more detailed information about each speaker.

Janet Dancey, M.D., FRCPC, Medical Oncologist, National Institutes of Health

David Gandara, M.D., University of California Davis Cancer Center, Sacramento, Calif.

David R. Gandara, MD, professor of medicine at the University of California, Davis School of Medicine is Associate Director of Clinical Research and Director of Thoracic Oncology at the University of California, Davis Cancer Center. He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group trials. He is the principal investigator for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is chair of the Southwest Oncology Group (SWOG) Lung Committee, and was co-chair, and continues to be a member, of the NCI-directed Investigational Drug Steering Committee. He has written over 300 articles, book chapters, abstracts and editorials. He is editor-in-chief of Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is a manuscript reviewer for eight additional journals. He also serves as President-elect and on the board of directors for the International Association for the Study of Lung Cancer (IASLC) and is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He also is chair of the NCI-directed Lung Correlative Science Committee. After receiving his medical degree from the University of Texas Medical Branch in Galveston, Dr. Gandara was an intern and resident at the Madigan Army Medical Center in Tacoma and a fellow at the Letterman Army Medical Center Presidio of San Francisco.

John Heymach, M.D, Medical Oncologist, M.D. Anderson Cancer Center

The overall goal of Dr. Heymach�s clinical, translational, and laboratory research is to advance the development of targeted agents, particularly angiogenesis inhibitors, for non-small cell lung cancer (NSCLC) and other solid tumors. Dr. Heymach received his B.A. magna cum laude in chemistry from Harvard, and his M.D. and Ph.D. (Neuroscience) from Stanford Medical School in 1998. He received his medical oncology training Dana-Farber/Partners Cancer Center Institute and Harvard Medical School, where he completed his medical oncology training Dr. Bruce Johnson, and his postdoctoral training with Dr. Judah Folkman at Children�s Hospital Boston. He was recruited to M.D. Anderson in 2005. His research efforts are focused on three areas: 1) the development of blood-based and proteomic markers to measure the biological activity of these agents and predict therapeutic response; 2) the molecular mechanisms that determine response or resistance to a given angiogenesis inhibitor; and 3) evaluation of the clinical efficacy of these agents rationally designed combination regimens. He has made significant contributions to the development and clinical translation of novel blood-based biomarkers such as circulating endothelial cells for VEGF pathway inhibitor effects, from the original murine studies to their utilization in several recent phase I and II trials, including a randomized phase II study in NSCLC of ZD6474. This trial showed prolonged progression-free survival and was brought forward into an ongoing phase III trial. Dr. Heymach has received a number of prestigious awards and grants, including an ASCO Career Development Award and Damon Runyon Clinical Investigator Award. He has investigated potential mechanisms of resistance to targeted agents, in murine models. Selected publications: Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pe�ek M, �p�sov� I, Belani CP, Bodrogi I, Gadgee S, Kennedy SJ, Hou J, Herbst RS. Vandetanib (ZD6474) plus docetaxel in patients with previously treated non-small cell lung cancer: results of a randomized, placebo-controlled phase I/II study. J Clin Oncol, 25 (27), 4270 (2007). Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor (GIST). Clin Can Res 13(9):2643-50, 2007. Lippman, S. M., and Heymach, J. V. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13:4035-41, 2007. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10:5732-40, 9/2004. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11:3514-22, 5/2005.

Anthony Shields, M.D., Ph.D., Medical Oncologist, Hudson-Webber Cancer Research Center

Anthony Shields, M.D., Ph.D., is the Associate Center Director for Clinical Research at Karmanos Cancer Institute and Professor of Medicine and Oncology at Wayne State University School of Medicine in Detroit, Michigan. Dr. Shields has a Ph.D. in Biology from the Massachusetts Institute of Technology and M.D. from Harvard University. His work focuses on the development and testing of tracers for use with positron emission tomography (PET) for the assessment of a variety of tumors (e.g. brain, lung, breast, and prostate cancers) and their response to treatment. He led the development of FLT {3�-fluorothymidine}; a promising tracer for tumor proliferation, which is being tested in centers worldwide. His group also developed the synthesis of [F-18] FMAU {1-(2�-deoxy-2�-fluoro-beta-D-arabinofuranosyl)-thymine}, which may provide an early measure to tumor response. He is working with a number of investigators to incorporate PET tracer studies into the development and assessment of new therapeutic options, particularly new targeted agent. To date, Dr. Shields has more than 90 peer-reviewed publications. Current research support includes NIH R01 and Department of Defense grants as principal investigator and grants from industry. As an Associate Director within the Karmanos Cancer Institute he oversees the clinical research operation, including the protocol review and monitoring process. He serves as an invited participant at NIH workshops, as an ad hoc reviewer for several federal grants, served as Chair of the Colon Cancer Committee for the Michigan Department of Community Health and as a PET Standards Advisory Committee Expert for the State of Michigan. Dr. Shields is also active in the Southwest Oncology Group, where he is sub-chair for colorectal cancer, Society of Nuclear Medicine, and American College of Radiology Imaging Network and was the 2005 recipient of the Peter Valk Distinguished Clinical Scientist Award from the Academy of Molecular Imaging. Selected Publications Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging. Epub 2008 Feb 12. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, Mangner TJ, Heilbrun LK, Muzik O. Analysis and reproducibility of [F-18] 3�-deoxy-3�-fluorothymidine PET imaging in patients with non-small cell lung cancer. Clin. Cancer Res. 14:4463-8. 2008. Nimmagadda S, Shields AF. The Role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev. DOI 10.1007/s10555-008-9148-5. 2008.

Streaming Audio with
PowerPoint Slides

(Code: 080)

Attendee/Member:

Attendee/Member-in-Training:

Attendee/Allied Member:

Attendee/Allied Non-Member:

Attendee/Student:

Attendee/Non-Member:

Member:

Non-Attendee/Member-in-Training:

Non-Attendee/Allied Member:

Non-Attendee/Allied Non-Member:

Residents, Member-in-Training, Students:

Members/Attendees Login